8C02 image
Entry Detail
PDB ID:
8C02
EMDB ID:
Title:
Structure of SLC40/ferroportin in complex with synthetic nanobody Sy3 in occluded conformation
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2022-12-15
Release Date:
2023-03-22
Method Details:
Experimental Method:
Resolution:
4.09 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Solute carrier family 40 member 1
Chain IDs:A
Chain Length:580
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Sybody3
Chain IDs:B
Chain Length:146
Number of Molecules:1
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Structures of ferroportin in complex with its specific inhibitor vamifeport.
Elife 12 ? ? (2023)
PMID: 36943194 DOI: 10.7554/eLife.83053

Abstact

A central regulatory mechanism of iron homeostasis in humans involves ferroportin (FPN), the sole cellular iron exporter, and the peptide hormone hepcidin, which inhibits Fe2+ transport and induces internalization and degradation of FPN. Dysregulation of the FPN/hepcidin axis leads to diverse pathological conditions, and consequently, pharmacological compounds that inhibit FPN-mediated iron transport are of high clinical interest. Here, we describe the cryo-electron microscopy structures of human FPN in complex with synthetic nanobodies and vamifeport (VIT-2763), the first clinical-stage oral FPN inhibitor. Vamifeport competes with hepcidin for FPN binding and is currently in clinical development for β-thalassemia and sickle cell disease. The structures display two distinct conformations of FPN, representing outward-facing and occluded states of the transporter. The vamifeport site is located in the center of the protein, where the overlap with hepcidin interactions underlies the competitive relationship between the two molecules. The introduction of point mutations in the binding pocket of vamifeport reduces its affinity to FPN, emphasizing the relevance of the structural data. Together, our study reveals conformational rearrangements of FPN that are of potential relevance for transport, and it provides initial insight into the pharmacological targeting of this unique iron efflux transporter.

Legend

Protein

Chemical

Disease

Primary Citation of related structures